Rhumbline Advisers Sells 8,850 Shares of Merck & Co., Inc. $MRK

Rhumbline Advisers lessened its position in shares of Merck & Co., Inc. (NYSE:MRK) by 0.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,100,358 shares of the company’s stock after selling 8,850 shares during the period. Rhumbline Advisers’ holdings in Merck & Co., Inc. were worth $344,143,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in MRK. Darwin Wealth Management LLC grew its holdings in Merck & Co., Inc. by 237.4% in the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after buying an additional 216 shares in the last quarter. Kilter Group LLC bought a new stake in shares of Merck & Co., Inc. in the second quarter valued at about $27,000. Bare Financial Services Inc grew its stake in shares of Merck & Co., Inc. by 51.9% in the second quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after acquiring an additional 125 shares in the last quarter. Barnes Dennig Private Wealth Management LLC increased its position in Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after acquiring an additional 266 shares during the period. Finally, Evolution Wealth Management Inc. acquired a new stake in Merck & Co., Inc. in the 2nd quarter worth about $31,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Short interest fell ~14.6% in January to ~28.7M shares (≈1.2% of float), lowering short‑pressure and reducing the odds of a short‑squeeze‑driven reversal. (Data: Jan. 30 short interest)
• Positive Sentiment: Bullish research argues Merck’s recent rally isn’t excess — analysts highlight extended Keytruda exclusivity, QLEX migration and pipeline/BD upside as durable revenue drivers. This supports longer‑term upside expectations. Merck: A Buy For 2026, But The Clock Is Still Ticking
• Positive Sentiment: Merck entered a strategic collaboration with Calla Lily Clinical Care to advance an intravaginal drug‑delivery platform (Callavid®), expanding non‑oncology device/partnered opportunities that could augment future topline or BD interest. Calla Lily Collaboration
• Neutral Sentiment: Merck reaffirmed solid fundamentals: recent quarter beat estimates, announced a $0.85 quarterly dividend (ex‑dividend March 16) and provided FY‑2026 EPS guidance. These support income/long‑term holders but may be largely priced in near term.
• Negative Sentiment: Large, high‑visibility insider sale: EVP Jennifer Zachary sold 121,573 shares (~$14.5M) at ≈$119.15 and materially reduced her stake — a prominent executive sale that can spook short‑term traders. Form 4 — Jennifer Zachary
• Negative Sentiment: Additional insider sales: CMO Chirfi Guindo sold 10,000 shares (~$1.18M) and other senior executives (including the CFO and another EVP) disclosed multi‑million dollar sales, amplifying negative sentiment from leadership selling. Form 4 — Chirfi Guindo CFO Sale Coverage
• Negative Sentiment: Some market commentary and at least one downgrade flag a near‑term balancing act — caution about valuation after a strong run and nearer‑term catalysts keeps trading volatility elevated. Balancing Act Article

Wall Street Analyst Weigh In

MRK has been the topic of a number of analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. Zacks Research downgraded Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research report on Friday, January 9th. TD Cowen lifted their price objective on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a report on Tuesday, January 20th. Cantor Fitzgerald increased their target price on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Finally, Morgan Stanley boosted their price target on Merck & Co., Inc. from $100.00 to $102.00 and gave the company an “equal weight” rating in a research note on Friday, December 12th. Eight research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $120.93.

Insiders Place Their Bets

In other news, CEO Robert M. Davis sold 47,434 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total value of $5,599,109.36. Following the completion of the transaction, the chief executive officer directly owned 443,602 shares in the company, valued at approximately $52,362,780.08. This represents a 9.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Chirfi Guindo sold 20,000 shares of the firm’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total value of $2,437,600.00. Following the sale, the chief marketing officer directly owned 80,615 shares in the company, valued at approximately $9,825,356.20. This trade represents a 19.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 320,176 shares of company stock worth $38,281,735 over the last 90 days. Insiders own 0.09% of the company’s stock.

Merck & Co., Inc. Trading Down 0.5%

Shares of MRK opened at $117.12 on Wednesday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.44 and a current ratio of 1.66. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $122.66. The firm has a market cap of $290.69 billion, a price-to-earnings ratio of 16.09, a PEG ratio of 2.20 and a beta of 0.28. The business’s fifty day moving average is $107.22 and its 200-day moving average is $93.75.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 45.22% and a net margin of 28.08%.The business had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same period last year, the firm posted $1.72 earnings per share. Merck & Co., Inc.’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.